Boxtel, Netherlands

Andreas Alphons Van Puijenbroek


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Andreas Alphons Van Puijenbroek: Innovator in miRNA Therapeutics

Introduction

Andreas Alphons Van Puijenbroek is a notable inventor based in Boxtel, Netherlands. He has made significant contributions to the field of molecular biology, particularly in the area of microRNA (miRNA) therapeutics. His innovative work focuses on the diagnostic and therapeutic applications of miRNA molecules in diseases associated with epithelial to mesenchymal transition (EMT).

Latest Patents

Van Puijenbroek holds a patent for a miRNA molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with EMT. This invention relates to the uses of a miRNA molecule or an equivalent that comprises at least 80 nucleotides and includes a motif with at least 98% identity to the motif represented by SEQ ID NO:1. This groundbreaking work has the potential to impact the diagnosis and treatment of various conditions linked to EMT.

Career Highlights

Andreas is currently associated with Interna Technologies B.V., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the exploration of miRNA applications in medical science.

Collaborations

He collaborates with esteemed colleagues such as Roeland Quirinus Jozef Schaapveld and Gerardus Wihelmus Christiaan Theodoor Verhaegh, contributing to a dynamic research environment that fosters innovation.

Conclusion

Andreas Alphons Van Puijenbroek's contributions to the field of miRNA therapeutics exemplify the impact of innovative research on medical science. His work not only enhances our understanding of molecular biology but also paves the way for new diagnostic and therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…